Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy

Alexandros G.Sfakianakis shared this article with you from Inoreader Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy Μέσω CRO : Last 20 articles The lead author with clinical stage I malignant pleural mesothelioma, epithelioid type, highly programmed cell death ligand 1 (PD-L1) positive, and BAP1 negative, experienced a prompt and exceptionally favorable response to pembrolizumab monotherapy. After cessation of treatment due to immune-related endocrinopathies, complete metabolic response on interim PET/CT scan was achieved. Two years after initial diagnosis, un ifocal tumor reactivation was addressed with successful pembrolizumab monotherapy rechallenge. Immunotherapy, typically not used as frontline treatment for malignant pleural mesothelioma, may provide an effective and durable response for some patients. Based on this single case study, epithelioid type tumors with strongly positive PD-L1 and BAP1-negative immunohistochemical markers may be well suited for treatment with immune checkpoint inhibitors such as pembrolizumab. Case Rep Oncol 2020;13:1483–1489 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.